Padoin C, Tod M, Perret G, Petitjean O
Departement de Pharmacotoxicologie, Hôpital Avicenne, Bobigny, France.
Antimicrob Agents Chemother. 1998 Jun;42(6):1463-9. doi: 10.1128/AAC.42.6.1463.
Oligopeptidic drugs such as beta-lactams and angiotensin-converting enzyme inhibitors share the same carriers in humans and animals, which results in possible pharmacokinetic interactions. To model such interactions, the effects of quinapril on cephalexin pharmacokinetics were investigated in rats. Blood cephalexin concentrations were measured by liquid chromatography, and the data were analyzed by a noncompartmental method and by fitting a bicompartmental model by a nonlinear mixed-effect modeling approach. Five groups of eight rats were examined. In the first three groups, cephalexin elimination kinetics after intra-arterial administration alone or in combination with quinapril given by the parenteral or the oral route were studied, and the occurrence of a pharmacokinetic interaction was not revealed. The absence of an effect of quinapril on cephalexin elimination after parenteral administration might be explained either by the higher affinity of cephalexin for the renal anionic transport system than that of quinapril or by the much higher concentrations of cephalexin than those of quinapril. In the last two groups, cephalexin was administered by the oral route alone or in combination with quinapril. The mean area under the concentration-time curve (AUC) for cephalexin was increased by ca. 30% by coadministration of quinapril (40.1 versus 31.4 mg.h/liter; P = 0.04). The mean elimination clearance of cephalexin was significantly decreased by quinapril, from 0.81 to 0.64 liter/h/kg of body weight (P < 0.05), probably by competitive inhibition of cephalexin secretion at the tubular level. The mean absorption rate constant of cephalexin was significantly lowered by quinapril (from 0.249 to 0.177 h-1; P < 0.01), without modification of the extent of absorption (89%). This pharmacokinetic interaction could be explained by competitive inhibition of cephalexin active transport by quinapril at the intestinal level.
β-内酰胺类和血管紧张素转换酶抑制剂等寡肽类药物在人和动物体内共用相同的载体,这可能导致药代动力学相互作用。为模拟此类相互作用,研究了喹那普利对大鼠头孢氨苄药代动力学的影响。通过液相色谱法测定血中头孢氨苄浓度,并采用非房室方法以及通过非线性混合效应建模方法拟合双房室模型对数据进行分析。对五组每组八只大鼠进行了检查。在前三组中,研究了单独动脉内给予头孢氨苄或与通过胃肠外或口服途径给予的喹那普利联合给药后的头孢氨苄消除动力学,未发现药代动力学相互作用。喹那普利对胃肠外给药后头孢氨苄消除无影响,这可能是由于头孢氨苄对肾阴离子转运系统的亲和力高于喹那普利,或者是由于头孢氨苄的浓度远高于喹那普利。在最后两组中,单独或与喹那普利联合口服给予头孢氨苄。联合给予喹那普利后,头孢氨苄的浓度-时间曲线下平均面积(AUC)增加了约30%(分别为40.1和31.4 mg·h/升;P = 0.04)。喹那普利使头孢氨苄的平均消除清除率显著降低,从0.81降至0.64升/小时/千克体重(P < 0.05),这可能是由于在肾小管水平竞争性抑制了头孢氨苄的分泌。喹那普利使头孢氨苄的平均吸收速率常数显著降低(从0.249降至0.177 h-1;P < 0.01),而吸收程度未改变(89%)。这种药代动力学相互作用可以用喹那普利在肠道水平竞争性抑制头孢氨苄的主动转运来解释。